Treatments and outcomes in Chinese patients with serologically active clinically quiescent systemic lupus erythematosus: a retrospective observational study

Table 4 Multivariable logistic regressive analysis: risk factors for flare in SACQ

	β	p	OR (95% CI)
Dose of corticosteroids^a (mg) when relapsed or at the end of follow-up	0.280	0.001	1.323 (1.129, 1.550)
Taking antimalarials when relapsed or at the end of follow-up	− 3.105	0.010	0.045 (0.004, 0.474)
Taking immunosuppressants when relapsed or at the end of follow-up	− 1.102	0.004	0.332 (0.156, 0.706)

Variables included in the model: dose of corticosteroids (mg) when relapsed or at the end of follow-up, taking antimalarials when relapsed or at the end of follow-up, taking immunosuppressants when relapsed or at the end of follow-up, duration of serological activity before SACQ (months), anti-dsDNA (+), and/or hypocomplementemia
^aCorticosteroid doses were converted to milligrams (mg) of prednisone equivalent

ISSN: 1478-6362